Gsk (GSK) Gains from Equity Investments (2015 - 2023)
Gsk (GSK) posted Gains from Equity Investments of $741.95 million for the quarter ended Jun 30, 2026, down 66.2% from $2.2 billion a year earlier and down 70.1% from the prior quarter.
Powered by 
Analysis
Gsk (GSK) Gains from Equity Investments (2015 - 2023) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Gains from Equity Investments at Gsk was $14.48 billion, up 74.5% year-over-year; for the year ended Dec 31, 2025, it came in at $8.29 billion, up 119.8% from the prior year.
- Annual Gains from Equity Investments shows a five-year compound annual growth rate of 9.4% (years ended Dec 2020 to Dec 2025).
- In prior years, Gsk's Gains from Equity Investments was $3.77 billion in the year ended Dec 31, 2024 (-42.9%), $6.6 billion in the year ended Dec 31, 2023, $7.43 million in the year ended Dec 31, 2022 (-99.6%) and $1.98 billion in the year ended Dec 31, 2021 (-62.6%).
- The figure for the quarter ended Jun 30, 2026 stands as the lowest quarterly Gains from Equity Investments since the quarter ended Sep 30, 2024.
- On a year-over-year basis, Gains from Equity Investments increased in four of the last seven quarters, with growth averaging 3.4%.
- The strongest year-over-year quarter for Gains from Equity Investments in the past five years was the quarter ended Mar 31, 2023, with growth of 313.9%; the weakest was the quarter ended Sep 30, 2024, with a decline of 95.7%.
- According to Business Quant data, Gains from Equity Investments for the three prior quarters was $2.48 billion (quarter ended Mar 31, 2026), $8.37 billion (quarter ended Dec 31, 2025) and $2.89 billion (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,224.11 Bn | 1,197.72 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 665.34 Bn | 585.20 Bn | 17.30 Bn |
| 3 | AbbVie | 515.72 Bn | 483.73 Bn | 13.12 Bn |
| 4 | Merck | 362.64 Bn | 325.58 Bn | 13.19 Bn |
| 5 | Novartis Ag | 315.51 Bn | 288.75 Bn | - |
| 6 | Astrazeneca | 289.26 Bn | 263.15 Bn | 13.26 Bn |
| 7 | Amgen | 249.20 Bn | 200.85 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 207.48 Bn | 182.59 Bn | 6.73 Bn |
| 9 | Pfizer | 167.49 Bn | 114.85 Bn | 12.56 Bn |
| 10 | Gsk | 102.08 Bn | 84.92 Bn | 8.73 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 12.41 Mn |
| Mar 31, 2023 | 1.22 Mn |
| Mar 31, 2020 | 17.95 Mn |
| Mar 31, 2018 | 54.25 Mn |
| Mar 31, 2015 | 855.41 Mn |
API Access
Gsk Gains from Equity Investments API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gains-from-equity-investments&ticker=GSK&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gains-from-equity-investments", "ticker": "GSK", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gains-from-equity-investments&ticker=GSK&period=max&api_key=YOUR_API_KEY");
const data = await res.json();